

To,
Head, Listing Compliance Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 542650

To,
Head, Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra – Kurla Complex, Bandra (East),
Mumbai – 400051

Scrip Symbol: METROPOLIS

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company would like to update on the following key business parameters for the quarter ended September 30, 2023.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended 30th September 2023. A detailed information update will follow once the Board approves the financial results for Q2FY24.

Company has reported a strong Q2FY24 with early double digit growth YoY for its core business (Revenue Incl. Hi-tech but Excl. Covid, Covid Allied & PPP Contracts) and also witnessed expansion in operating margins sequentially. The growth was driven by volume growth in the specialized and wellness segments, as well as B2C revenue growth.

The company also saw a reduction in competitive intensity and an increase in prices by multiple peers in the diagnostics industry. With its swift actions, strategic initiatives & network expansion strategies, the company is well-positioned to capitalize on these positive developments.

Please find below the key highlights of Q2FY24:

1. Core business (Revenue Incl. Hi-tech but Excl. Covid, Covid Allied & PPP Contracts) revenue grew by 13% Y-o-Y. Revenue growth was largely driven by volume growth demonstrating strong customer acquisition.
2. Operating margins grew Q-o-Q on account of higher revenues leading to operating leverage & product mix
3. B2C revenue grew ~15% on a Y-o-Y basis largely on the back of volume and new patient growth
4. Premium wellness segment is the fastest growing segment in Q2FY24
5. Gross Debt as on 30th September 2023 stood at ~Rs. 44 Crs.

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

The Quarterly Business Update is on a Consolidated basis. The Financial results of Q2FY24 is subject to review by Auditors. The Company will continue to provide the Business update for the current financial year.

Thanking you,

Yours faithfully

For **Metropolis Healthcare Limited**

Neha Shah
Interim Company Secretary
& Compliance Officer
Membership No: A51465

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.